BioTelemetry (BEAT) Upgraded to “Buy” by BidaskClub

BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

Other analysts have also issued research reports about the company. Zacks Investment Research lowered BioTelemetry from a hold rating to a sell rating in a research note on Thursday, February 8th. Dougherty & Co reaffirmed a buy rating and issued a $40.00 target price on shares of BioTelemetry in a research note on Wednesday, November 8th. SunTrust Banks assumed coverage on BioTelemetry in a research note on Monday, October 23rd. They issued a buy rating and a $41.00 target price for the company. Finally, Raymond James Financial assumed coverage on BioTelemetry in a research note on Thursday, October 26th. They set an outperform rating and a $37.00 price objective for the company. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $42.86.

Shares of BioTelemetry (NASDAQ BEAT) traded up $0.40 on Wednesday, reaching $33.35. The company’s stock had a trading volume of 320,600 shares, compared to its average volume of 407,504. The stock has a market capitalization of $1,067.85, a price-to-earnings ratio of 25.85, a P/E/G ratio of 1.46 and a beta of 0.67. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $39.20.

Several large investors have recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. purchased a new stake in BioTelemetry in the third quarter worth $109,000. First Dallas Securities Inc. purchased a new stake in BioTelemetry in the fourth quarter worth $133,000. Piedmont Investment Advisors LLC purchased a new stake in BioTelemetry in the second quarter worth $207,000. UBS Asset Management Americas Inc. purchased a new stake in BioTelemetry in the second quarter worth $208,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in BioTelemetry in the second quarter worth $212,000. 83.27% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2018/02/15/biotelemetry-beat-upgraded-to-buy-by-bidaskclub.html.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply